Increased risk of influenza among vaccinated adults who are obese

S D Neidich, W D Green, J Rebeles, E A Karlsson, S Schultz-Cherry, T L Noah, S Chakladar, M G Hudgens, S S Weir, M A Beck, S D Neidich, W D Green, J Rebeles, E A Karlsson, S Schultz-Cherry, T L Noah, S Chakladar, M G Hudgens, S S Weir, M A Beck

Abstract

Background: Influenza infects 5-15% of the global population each year, and obesity has been shown to be an independent risk factor for increased influenza-related complications including hospitalization and death. However, the risk of developing influenza or influenza-like illness (ILI) in a vaccinated obese adult population has not been addressed.

Objective: This study evaluated whether obesity was associated with increased risk of influenza and ILI among vaccinated adults.

Subjects and methods: During the 2013-2014 and 2014-2015 influenza seasons, we recruited 1042 subjects to a prospective observational study of trivalent inactivated influenza vaccine (IIV3) in adults. A total of 1022 subjects completed the study. Assessments of relative risk for laboratory confirmed influenza and ILI were determined based on body mass index. Seroconversion and seroprotection rates were determined using prevaccination and 26-35 days post vaccination serum samples. Recruitment criteria for this study were adults 18 years of age and older receiving the seasonal trivalent inactivated influenza vaccine (IIV3) for the years 2013-2014 and 2014-2015. Exclusion criteria were immunosuppressive diseases, use of immunomodulatory or immunosuppressive drugs, acute febrile illness, history of Guillain-Barre syndrome, use of theophylline preparations or use of warfarin.

Results: Among obese, 9.8% had either confirmed influenza or influenza-like-illness compared with 5.1% of healthy weight participants. Compared with vaccinated healthy weight, obese participants had double the risk of developing influenza or ILI (relative risk=2.01, 95% CI 1.12, 3.60, P=0.020). Seroconversion or seroprotection rates were not different between healthy weight and obese adults with influenza or ILI.

Conclusions: Despite robust serological responses, vaccinated obese adults are twice as likely to develop influenza and ILI compared with healthy weight adults. This finding challenges the current standard for correlates of protection, suggesting use of antibody titers to determine vaccine effectiveness in an obese population may provide misleading information.

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Influenza HAI and MN antibody titers for influenza confirmed and ILI participants and uninfected controls. Pre and post influenza vaccination HAI titers of participants with influenza confirmed and ILI against (a) A/California/pdm2009, (b) A/Texas/50/2012 and (c) A/Switzerland/9715293/2013. Pre and post vaccination titers were not statistically different among healthy weight (white with open circles), overweight (checkered with black circles) or obese (grey with grey circles) participants. Pre and post influenza vaccination HAI titers in participants with ILI (open circles and grey boxes) and demographically matched uninfected controls (black circles and black boxes) for (d) A/California/pdm2009, (e) A/Texas/50/2012 and (f) A/Switzerland/9715293/2013. Pre and post vaccination titers were not statistically different between ILI participants and non-illness reporting matched controls. Pre and post influenza vaccination HAI (g, h, i) and MN (j,k) titers in participants with confirmed influenza (open circles) and matched uninfected controls (black circles). Pre and post HAI or MN vaccination titers were not statistically different between confirmed influenza participants and matched controls. a,b: n=14 for healthy weight, n=16 for overweight, n=44 obese; c: n=9 healthy weight, n=9 for overweight, n=25 for obese. d, e: n=74; f: n=43, g, h, j, k: n=10; I: n=7.

References

    1. WHO/Influenza (Seasonal) WHO; 2016. [Accessed November 10, 2016].
    1. Patterson KD, Pyle GF. The geography and mortality of the 1918 influenza pandemic. Bull Hist Med. 1991;65:4–21.
    1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179–186.
    1. Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. New Engl J Med. 2000;342:232–239.
    1. Valdez R, Narayan KM, Geiss LS, Engelgau MM. Impact of diabetes mellitus on mortality associated with pneumonia and influenza among non-Hispanic black and white US adults. AJPH. 1999;89:1715–1721.
    1. Sandoval C, Walter SD, Krueger P, et al. Risk of hospitalization during influenza season among a cohort of patients with congestive heart failure. Epidemiol Infect. 2007;135:574–582.
    1. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998;148:1094–1102.
    1. Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302:1896–1902.
    1. Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or uncomplicated influenza illness: systematic review and meta-analysis. BMJ. 2013;347:f5061.
    1. Liu B, Havers F, Chen E, et al. Risk factors for influenza A(H7N9) disease-China, 2013. Clin Infect Dis. 2014;59:787–794.
    1. Centers for Disease Control and Prevention. [Acessed November 10, 2016];Adult Obesity Facts. .
    1. World Health Organization. [Accessed November 10, 2016];Adult obesity facts.
    1. Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines (Basel) 2015;3:373–389.
    1. Trombetta CM, Montomoli E. Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016;15:967–976.
    1. Coudeville L, Bailleux F, Riche B, Megas F, Andre P, Ecochard R. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a Bayesian random-effects model. BMC Med Res Methodol. 2010;10:18.
    1. Black S, Nicolay U, Vesikari T, et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J. 2011;30:1081–1085.
    1. Centers for Disease Control and Prevention. [Accessed November 10, 2016];Overview of Influenza Surveillance in the United States. .
    1. Webster R, Cox N, Stohr K. World Health Organization Manual on Animal Influenza Diagnosis and Surveillance. WHO; Geneva: 2002.
    1. Karlsson EA, Meliopoulos VA, Savage C, Livingston B, Mehle A, Schultz-Cherry S. Visualizing real-time influenza virus infection, transmission and protection in ferrets. Nat Commun. 2015;6:6378.
    1. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2016.
    1. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the United States, 2005–2014. JAMA. 2016;315:2284–2291.
    1. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA. 2003;289:76–79.
    1. Xie H, Wan XF, Ye Z, et al. H3N2 mismatch of 2014–15 northern hemisphere influenza vaccines and head-to-head comparison between human and ferret antisera derived antigenic maps. Sci Rep. 2015;5:15279.
    1. Fan W, Chen XF, Shen C, Guo ZR, Dong C. Hepatitis B vaccine response in obesity: A meta-analysis. Vaccine. 2016;34:4835–4841.
    1. Eliakim A, Schwindt C, Zaldivar F, Casali P, Cooper DM. Reduced tetanus antibody titers in overweight children. Autoimmunity. 2006;39:137–141.
    1. Painter SD, Ovsyannikova IG, Poland GA. The weight of obesity on the human immune response to vaccination. Vaccine. 2015;33:4422–4429.
    1. Paich HA, Sheridan PA, Handy J, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. Obesity. 2013;21:2377–2386.
    1. Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond) 2012;36:1072–1077.
    1. McElhaney JE, Xie D, Hager WD, et al. T cell responses are better correlates of vaccine protection in the elderly. J Immunol. 2006;176:6333–6339.
    1. Cheng LW, Huang SW, Huang LM, et al. Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine. J Virol Methods. 2012;182:43–49.
    1. Murphy R, Fragaszy EB, Hayward AC, Warren-Gash C. Investigating obesity as a risk factor for influenza-like illness during the 2009 H1N1 influenza pandemic using the Health Survey for England. Influenza Other Respir Viruses. 2017;11:66–73.
    1. Karlsson EA, Hertz T, Johnson C, Mehle A, Krammer F, Schultz-Cherry S. Obesity outweighs protection conferred by adjuvanted influenza vaccination. MBio. 2016;7:e01144–16.
    1. Smit MA, Wang HL, Kim E, et al. Influenza vaccine is protective against laboratory-confirmed influenza in obese children. Ped Infect Dis J. 2016;35:440–445.
    1. Callahan ST, Wolff M, Hill HR, et al. Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. J Infect Dis. 2014;210:1270–1274.
    1. Esposito S, Giavoli C, Trombetta C, et al. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. Vaccine. 2016;34:56–60.
    1. Talbot H, Coleman L, Crimin K, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine. 2012;30:3937–3943.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa